CAR-T Cell Therapy Development Service for Multiple Myeloma (MM)
In the formulation of a CAR-T cell therapy development plan for multiple myeloma, our company engages in in-depth communication with customers. Our services encompass the entire drug development process, from discovery to IND application, including target discovery & validation, CAR-T cell construct design & screening, in vitro & in vivo evaluation.
Download the PDFOur Services
- Target Discovery & Validation - Our experts utilize cutting-edge technologies to identify and validate critical targets specific to multiple myeloma cells, ensuring precise and effective interventions.
- Construction of CAR – Our company meticulously design and optimize chimeric antigen receptors (CARs) to ensure high specificity, potency, and minimal off-target effects.
- CAR-T Cell Construction & Screening - Our advanced platforms facilitate the efficient engineering, production, and screening of CAR-T cells, ensuring high efficacy and safety profiles.
- In Vtro Evaluation - Our company conduct comprehensive in vitro assays to evaluate the CAR-T cell functions, including cytotoxicity and cytokine release.
- In Vivo Evaluation - Our in vivo experiments in preclinical models assess the therapeutic efficacy and potential toxicity of the CAR-T cells in a controlled environment.
We aim to drive advancements in the development of CAR-T Cell Therapy for Multiple Myeloma and are dedicated to aiding our partners in their efforts to launch groundbreaking therapies. If you are interested in our services, please contact us as soon as possible.
Relative Platforms
Cell Therapy Development
Gene Therapy Development
Resource Download Request
Please complete the form to download the requested resources.